Hangzhou Tongzhou Biotechnology Co., Ltd. announced that it expects to receive CNY 19 million in funding from Hangzhou Alltest Biotech Co., Ltd.
January 08, 2023
Share
Hangzhou Tongzhou Biotechnology Co., Ltd. announced that it will receive CNY 19 million in equity round of funding on January 9, 2023. The transaction will include participation from returning investor Hangzhou Alltest Biotech Co., Ltd. The transaction has been approved in the nineteenth meeting of the second board of directors and the fourteenth meeting of the second board of supervisors.
Hangzhou Alltest Biotech Co Ltd is a China-based company mainly engaged in the development and production of in vitro diagnostic reagents. The Companyâs main products are rapid diagnostic reagents, including drug and drug abuse testing, infectious disease testing, womenâs health testing, tumor testing, and heart marker testing. The Company's products are widely used in clinical testing, on-site testing and personal health management, especially in some new drug testing, new coronavirus testing, tropical infectious disease testing, respiratory all-in-one inspection, pediatric diarrhea all-in-one inspection and all-in-one joint inspection of fecal occult blood and other fields. The Company's main business is mainly distributed in overseas regions.
HANGZHOU ALLTEST BIOTECH CO., LTD. 
